Peroxisome proliferator-activated receptor γ (PPAR γ), a member of the nuclear receptor superfamily, is a ligand-activated transcription factor that plays an important role in the control of a variety of physiological processes. The last decade has witnessed an increasing interest for the role played by the agonists of PPAR γ in antiangiogenesis, antifibrosis, anti-inflammation effects and in controlling oxidative stress response in various organs. As the pathologic mechanisms of major blinding diseases, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), keratitis, and optic neuropathy, often involve neoangiogenesis and inflammation- and oxidative stress-mediated cell death, evidences are accumulating on the potentia...
The peroxisome proliferator-activated receptor γ (PPARγ) belongs to the nuclear hormone receptor sup...
Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes and rema...
Although glucose-lowering treatment shows some risk lowering effects in cardiovascular diseases, ris...
Peroxisome proliferator-activated receptor (PPARs) are ligand-activated transcription factors that e...
Pericyte degeneration is an early event in diabetic retinopathy and plays an important role in progr...
Peroxisome proliferator-activated receptor (PPAR)β/δ is a member of the nuclear receptor superfamily...
Peroxisome proliferator-activated receptor (PPAR)β/δ is a member of the nuclear receptor superfamily...
It has been shown that peroxisome proliferators-activated receptor gamma (PPARγ) is beneficial for c...
Retinal vascular leakage, inflammation, and neovascularization (NV) are features of diabetic retinop...
Peroxisome proliferator-activated receptor a (PPARa) agonism in ocular inflammation has not been tho...
Peroxisome-proliferator activated receptor-alpha (PPARα) is a broadly expressed nuclear hormone rece...
The burden of neurodegenerative diseases in the central nervous system (CNS) is increasing globally....
Peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription factor that...
Diabetic retinopathy (DR) is a common neurovascular complication of type 1 diabetes. Current therape...
Diabetic retinopathy, a microvascular complication of diabetes mellitus, is major cause of non-inher...
The peroxisome proliferator-activated receptor γ (PPARγ) belongs to the nuclear hormone receptor sup...
Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes and rema...
Although glucose-lowering treatment shows some risk lowering effects in cardiovascular diseases, ris...
Peroxisome proliferator-activated receptor (PPARs) are ligand-activated transcription factors that e...
Pericyte degeneration is an early event in diabetic retinopathy and plays an important role in progr...
Peroxisome proliferator-activated receptor (PPAR)β/δ is a member of the nuclear receptor superfamily...
Peroxisome proliferator-activated receptor (PPAR)β/δ is a member of the nuclear receptor superfamily...
It has been shown that peroxisome proliferators-activated receptor gamma (PPARγ) is beneficial for c...
Retinal vascular leakage, inflammation, and neovascularization (NV) are features of diabetic retinop...
Peroxisome proliferator-activated receptor a (PPARa) agonism in ocular inflammation has not been tho...
Peroxisome-proliferator activated receptor-alpha (PPARα) is a broadly expressed nuclear hormone rece...
The burden of neurodegenerative diseases in the central nervous system (CNS) is increasing globally....
Peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription factor that...
Diabetic retinopathy (DR) is a common neurovascular complication of type 1 diabetes. Current therape...
Diabetic retinopathy, a microvascular complication of diabetes mellitus, is major cause of non-inher...
The peroxisome proliferator-activated receptor γ (PPARγ) belongs to the nuclear hormone receptor sup...
Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes and rema...
Although glucose-lowering treatment shows some risk lowering effects in cardiovascular diseases, ris...